Positive Sector Outlook Bodes Well for Riot Platforms Inc. (RIOT)

Despite a large dip since precocious October, Riot Platforms Inc. (NASDAQ:RIOT) is up by much than 36% successful 2025. Despite that, the broader expert sum estimates a 95% upside for the banal from the existent level, with a statement 1-year median terms people of $27.19. The banal has received sum from 16 analysts, with 100% Buy ratings arsenic of December 24 closing.

On December 22, Citi expert Peter Christiansen reiterated his Buy standing for Riot Platforms Inc. (NASDAQ:RIOT). Although the expert has lowered his terms people connected the banal from $28 to $23, helium remains bullish. With Christiansen’s revised terms target, the banal present has an upside imaginable of much than 65%.

Despite his downward revision of the people price, Christiansen has a affirmative assemblage outlook for the coming year, which volition supply enactment to the stock. The expert believes that legislative reforms relating to AI infrastructure information centers volition beryllium to beryllium a large catalyst for Riot Platforms Inc. (NASDAQ:RIOT).

Riot Platforms Inc. (NASDAQ:RIOT) is simply a supplier of large-scale integer infrastructure and information centers, with a superior absorption connected bitcoin mining. The institution deploys a vertically integrated strategy to cater to the increasing requirements for high-density computing. They run bitcoin mining, engineering and fabrication facilities crossed the United States.

While we admit the imaginable of RIOT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.